Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; ZN A 1041 (Primary)
  • Indications Advanced breast cancer; Brain metastases; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Suzhou Zanrong Pharmaceutical Technology

    • Most Recent Events

    • 30 Jul 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.
    • 06 Jun 2023 Results from Part 1a, 1b and 1c (cut off : Dec 02, 2022), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 09 May 2023 According to a Zion Pharma media release, Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top